Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer

This publication has 60 references indexed in Scilit:

• Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
  Annals of Oncology, 2023
• MDM2- an indispensable player in tumorigenesis
  Molecular Biology Reports, 2023
• mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease
  International Journal of Cancer, 2021
• Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
  Investigational New Drugs, 2019
• MDM2 and mitochondrial function: One complex intersection
  Biochemical Pharmacology, 2019
• Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
  International Journal of Cancer, 2018
• MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population
  Breast Cancer Research and Treatment, 2018
• Clinical implications of the intrinsic molecular subtypes of breast cancer
  The Breast, 2015
• MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis
  Molecular Biology Reports, 2011
• mdm2 expression is induced by wild type p53 activity.
  The EMBO Journal, 1993